ASIT biotech is a clinical stage (Phase 3) biopharmaceutical company publicly listed on EURONEXT (Brussels & Paris).
ASIT biotech’s mission is to lead an evolution in allergy therapeutics by creating a new generation of highly effective and efficient immunotherapy options for respiratory and food allergies. Our goal is to generate breakthrough treatments that deliver rapid, recognizable improvement in the life of allergy patients, within weeks rather than months or years following treatment initiation.
- ASIT biotech obtains a second extension of its reprieve for 4 months Wednesday, 07 October 2020
- ASIT biotech presents its 2020 half year results and provides a business update until end 2020 Wednesday, 30 September 2020
- ASIT biotech signs a preliminary partnership agreement and requests an extension of his suspension of 2 months Sunday, 20 September 2020 All ASIT news